Organon furnishes supplemental non-GAAP Q2 2026 metrics; merger with Sun Pharma pending

Organon & Co.

Company released Q2 2026 financial results via Form 10-Q, not a press release, due to pending merger with Sun Pharmaceutical Industries.
Supplemental non-GAAP metrics for Q2 2026 are furnished in Exhibit 99.1 but no specific figures are provided in the filing text.
Customary earnings press release and conference call suspended for the quarter.
Non-GAAP measures are intended to supplement GAAP results; full GAAP disclosures are in the 10-Q filed July 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.